Form D · Biotechnology
Dermata Therapeutics, LLC
San Diego, CA · CIK 0001632047
Offering snapshot reported Dec 10, 2020 · SEC filing
- Reported sold
- $3M Indefinite offering
- Investors reported
- 37 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 17, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 10, 2020 | Initial | $3,000,000 | No comparison | 37 | SEC filing |
| May 7, 2018 | Initial | $6,906,244 | No comparison | 49 | SEC filing |
| May 7, 2018 | Initial | $5,000,000 | No comparison | 49 | SEC filing |
| Jun 12, 2015 | Initial | $651,305 | No comparison | 7 | SEC filing |
| Feb 3, 2015 | Initial | $608,050 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-382898
Source: Form D, filed Dec 10, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David F. Hale | Director, Executive, Promoter |
| N/A Hale Bio Pharma Ventures, Llc | Executive, Promoter |
| Tom Insley | Executive |
| Chris Nardo | Executive |
| Gerald T. Proehl | Director, Executive, Promoter |
| Wendell Wierenga | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3525 Del Mar Heights Rd Suite 322
San Diego, CA, 92130
San Diego, CA, 92130